UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
AstraZeneca PLC
(Exact name of registrant as specified in its charter)
| England and Wales (State or other jurisdiction of incorporation or organization) |
Not Applicable (I.R.S. Employer | |
|
1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge England (Address of principal executive offices) |
CB2 0AA (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title of each class to be so registered |
Name of each exchange on which each class is to be registered | |
|
3.500% Notes due 2023 Floating Rate Notes due 2023 4.000% Notes due 2029 4.375% Notes due 2048 |
New York Stock Exchange New York Stock Exchange New York Stock Exchange New York Stock Exchange |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. o
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. o
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-214756
Securities to be registered pursuant to Section 12(g) of the Act: None.
Item 1. Description of Registrant’s Securities to Be Registered.
The Registrant filed with the Securities and Exchange Commission (the “Commission”) on November 22, 2016 a Registration Statement on Form F-3 (the “Registration Statement”) relating to the Registrant’s Debt Securities. The Registration Statement was effective upon filing with the Commission in accordance with Rule 462(e) of the Securities Act of 1933, as amended (the “Securities Act”). On November 22, 2016, the Registrant filed a prospectus dated November 22, 2016 with the Commission pursuant to Rule 424(b)(3) under the Securities Act (the “Prospectus”). On August 14, 2018, the Registrant filed a preliminary prospectus supplement dated August 14, 2018 with the Commission pursuant to Rule 424(b)(2) under the Securities Act. On August 16, 2018, the Registrant filed a final prospectus supplement dated August 14, 2018 with the Commission pursuant to Rule 424(b)(2) under the Securities Act (the “Prospectus Supplement”). The Prospectus Supplement and the Prospectus are incorporated herein by reference to the extent set forth below.
Reference is made to the information set forth under the headings “Description of Debt Securities” on pages 12 through 24 and “Certain UK and US Federal Tax Considerations” on pages 28 through 35 of the Prospectus; and to the information set forth under the heading “Description of Notes” on pages S-18 to S-23 and “Taxation” on page S-24 of the Prospectus Supplement, which information is incorporated herein by reference.
Item 2. Exhibits.
| 1.1 | Registration Statement on Form F-3, including the Prospectus (incorporated herein by reference to the Registrant’s Registration Statement on Form F-3 (File No. 333- 214756)). |
| 2.1 | Prospectus Supplement (incorporated herein by reference to the Registrant’s filing with the Commission on August 16, 2018 pursuant to Rule 424(b)(2)). |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| Dated: August 17, 2018 |
ASTRAZENECA PLC
| ||
| By: | /s/ Adrian Kemp | ||
| Name: | Adrian Kemp | ||
| Title: | Company Secretary | ||